Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $102000.0.

  • Altimmune's Change in Accured Expenses rose 10215.1% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $408000.0, marking a year-over-year increase of 13852.69%. This contributed to the annual value of -$112000.0 for FY2024, which is 9405.2% up from last year.
  • Altimmune's Change in Accured Expenses amounted to $102000.0 in Q3 2025, which was up 10215.1% from -$365000.0 recorded in Q2 2025.
  • Altimmune's 5-year Change in Accured Expenses high stood at $11.0 million for Q3 2021, and its period low was -$9.2 million during Q4 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$1.5 million (2022), whereas its average is -$45421.1.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 83499.54% in 2021, then tumbled by 39199.51% in 2024.
  • Quarter analysis of 5 years shows Altimmune's Change in Accured Expenses stood at -$9.2 million in 2021, then soared by 76.54% to -$2.2 million in 2022, then surged by 165.82% to $1.4 million in 2023, then skyrocketed by 66.55% to $2.4 million in 2024, then tumbled by 95.7% to $102000.0 in 2025.
  • Its last three reported values are $102000.0 in Q3 2025, -$365000.0 for Q2 2025, and -$1.7 million during Q1 2025.